NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research

        • Research Overview
        • Clinical Research Facility
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient & Public Involvement
    • Getting involved with research
    • View and register for involvement opportunities
    • Patient & Public Groups
    • Patient and Public Involvement Advisory Group
    • Diversity in Research Group
    • Oxford Blood Group
    • Case Studies
    • PPIE Strategy
    • PPIE News
    • PPI Researcher Guidance
    • Researchers: Post a PPIE opportunity
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Modernising Medical Microbiology and Big Infection Diagnostics > Oxford team use DNA sequencing and patient data to halt infection outbreak

Oxford team use DNA sequencing and patient data to halt infection outbreak

3 October 2018 · Listed under Modernising Medical Microbiology and Big Infection Diagnostics, Translational Data Science

Clinical and research teams at Oxford University Hospitals (OUH) NHS Foundation Trust, using infection prevention and control best practice, whole genome sequencing and electronic patient data, have halted an outbreak of a potentially deadly fungal pathogen after detecting that multi-use patient equipment was responsible.

The breakthrough at the John Radcliffe Hospital is significant as this is the first time an outbreak of Candida auris (C. auris) has been completely ended with a clear understanding of the cause.

The study, published on 3 October by the New England Journal of Medicine, was conducted by the Infection, Prevention and Control and Neurosciences Intensive Care Unit (ICU) teams from OUH, the University of Oxford’s Nuffield Department of Medicine, the Big Data Institute and the NIHR Health Protection Research Unit and Public Health England, and supported by the NIHR Oxford Biomedical Research Centre.

The lead investigator, Dr David Eyre, Research Fellow in Infectious Diseases at the Big Data Institute, said: “It is very pleasing that our research has led to the C. auris outbreak being stopped. There are a number of hospitals in the UK and around the world that have been unable to halt their outbreaks. Working out how it is transmitted should help to contain its spread worldwide.”

“Such is the nature of this pathogen that we must remain vigilant, and we’re delighted that, since we changed our approach as a result of our findings, we have had no further cases.”

C. auris is an emerging, multi-drug resistant fungal pathogen recently associated with outbreaks worldwide, often in intensive care units. In some patients, C. auris can enter the bloodstream and spread throughout the body, causing serious infection.

The researchers investigated a large C. auris outbreak at the John Radcliffe Hospital’s Neurosciences ICU between 2015 and 2017, during which 70 patients were identified as being colonised or infected with C. auris.

Using whole genome sequencing of patient and environmental isolates, combined with electronic health record data, they studied possible transmission routes, risk factors for colonisation and the molecular epidemiology of the outbreak.

Patients in Neurosciences ICU were regularly screened for C. auris, as were those on the adjacent Neurosciences ward. Samples were also taken from the environment, focusing on sampling high-touch areas and multi-use devices.

“We found that C. auris was rarely detected in the general environment; there was no trace of the organism on surfaces within the unit and only 1 out of 16 air samples was positive,” Dr Eyre explained.

“However, we did find C. auris on multi-use patient equipment, particularly temperature probes. There were close genetic matches between C. auris isolated from patients and from these thermometers. We found that having their temperature monitored with one of these probes was an important risk factor for acquiring C. auris. And unlike with pathogens like C. difficile, bed proximity did not appear to be a factor in transmission.

“So our research clearly showed that environmental survival appears to be key to Candida auris’s persistence and transmission in healthcare settings. This led to us implementing successful infection control measures to contain the outbreak – including removing multi-use skin surface thermometers from use,” he said.

Professor Derrick Crook, Director of National Infection Service at Public Health England and Antimicrobial Resistance Theme Lead at the NIHR Oxford Biomedical Research Centre, said: “This study will feed directly into healthcare guidelines regarding the use of multi-use equipment, and in particular the decontamination of this equipment in the event of future outbreaks.

“Although a relatively small number of patients in the Oxford study had clinically significant C. auris infections, such infections can have serious consequences for the kind of vulnerable patients admitted to intensive care units, particularly as C. auris is highly resistant to many anti-fungal agents. The action that was taken as a result of this research undoubtedly prevented more patients becoming colonised and infected.”

← UK-led study marks shift towards genetic era in tackling TB
Award-winning citizen science project tackling TB gets millionth classification →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2023 NIHR Oxford Biomedical Research Centre